sub:assertion { d:DB05480v:identifier "DB05480" ; v:namespace "drugbank" ; v:uri "http://bio2rdf.org/drugbank:DB05480" ; v:x-identifiers.org <http://identifiers.org/drugbank/DB05480> ; dv:drugbank-id "DB05480" ; dv:x-cas <http://bio2rdf.org/cas:> ; dct:description """PBI-1402 is a small molecule synthetic compound with oral Bioavailability. The compound activates neutrophils, enhancing their survival and activation with comparable efficacy to GM-CSF, G-CSF and EPO, which are currently used to treat anemia. However, it has been shown that when co-administered with these compounds, effects are additive, making PBI-1402 an excellent candidate for combination therapy and asserting its independent mechanism of action. PBI-1402 appears to work on the PMN pathway, but its specific binding properties are not known. PBI-1402 has a dual therapeutic action; as a chemoprotectant and hematopoietic progenitor stimulator. Since it stimulates immune activity, it has been considered as a candidate for cancer treatment as well as anemia."""@en ; dct:identifier "drugbank:DB05480" ; dct:title "PBI-1402"@en ; adv:Drug ; rdfs:label "PBI-1402 [drugbank:DB05480]"@en ; rdfs:seeAlso <http://www.drugbank.ca/drugs/DB05480> . }